MRPlus®

on 11月 24, 2022

MRPlus ^® – Online engagement service that distributes medical information from pharmaceutical companies to 200,000 physicians

MRPlus^® is a service that distributes “medical information provided by pharmaceutical companies” via the Internet to CareNet’s 200,000 physicians.

This “medical information” includes information on the medicinal action and proper use of drugs, as well as the pathophysiology, diagnosis, treatment, and promotion of target diseases.

MRPlus^® contents are delivered on-demand in the form of video contents or slides in a story format designed to be easily understood by physicians who are too busy in their daily lives to meet with pharmaceutical company representatives.

Physicians can access the service whenever and wherever it is convenient for them and obtain useful medical information instantly and efficiently in a short time.

The most distinctive feature of MRPlus^® is its navigation function (“MRPlus^® Navigation Board”*), which provides timely feedback to pharmaceutical companies on the responses of physicians to their prescription requests, and this function also creates opportunities for MR (medical representatives) to effectively meet with physicians.

*Patented functions

By utilizing “MRPlus^®”, pharmaceutical companies will be able to reliably deliver information and messages to more than 200,000 physicians, thus providing a powerful backup tool for tomorrow’s sales activities.

CareNet will take care of everything from distribution to insight acquisition and reporting, thus reducing the workload on your company.

*MRPlus^® is the registered trademark of CareNet.

Value provided by MRPlus^®

・Communicating information and messages that pharmaceutical companies want to deliver to more than 200,000 physicians (algorithmic delivery).

・The segmentation of physicians can be categorized through a questionnaire, and optimal content can be delivered according to the segmentation (algorithmic delivery).

・A viewing completion rate of more than 90%* through a system that arouses physicians’ interest in diseases and drugs.

・Viewing logs and insights from physicians who came into contact with the information: 90% responded to the survey*.

・Target physicians proactively seek additional information, thus creating a “point of contact” that leads to a request for a visit by a MR (medical representative).

*Acquired a business model patent for the above viewing process.

・Develop efficient and effective marketing communication measures in the face of declining opportunities for face-to-face information provision.

・The progress of the recognition and understanding of marketing messages can be monitored through questionnaires, and the Plan-Do-Check-Act (PDCA) cycle can be implemented.

Changes in Physician Member Behavior through Viewing MRPlus^® Contents

CareNet member physicians deepen their understanding of the information transmitted by pharmaceutical companies as they proceed one by one to obtain drug information, respond to questionnaires, and request contact with pharmaceutical companies.

Why is MRPlus^® chossen?

Case Study

Owing to the COVID-19 disaster and the visitation restrictions, opportunities for MR(medical representatives) to provide information to physicians face-to-face decreased…

We want to provide information efficiently and link it to the visit activity!

Measures that take advantage of the characteristics of “e” and “MR”

・Characteristics of “e”: Messages can be communicated widely, repeatedly, and correctly without human bias.

・Characteristics of MR(medical representatives): They provide information that meets the needs of individual physicians.

→ Creating a lead to “closing” as the role of MR only, while taking advantage of the characteristics of “e”.
→ Efficient creation of opportunities for MR to visit physicians, while opportunities for MR to visit physicians are being curtailed owing to the COVID-19 disaster.

MRPlus^® Survey Features

MRPlus^® uses an algorithmic delivery function to deliver contents optimized for each type of physician segment.

In addition, MRPlus^® can obtain survey responses from approximately 90-95%* of the viewing physicians, enabling the evaluation of the delivered contents and the confirmation of prescription intentions and needs, leading to activities aimed at achieving the marketing goals of pharmaceutical companies.

・Capable of obtaining response data such as message transmission, prescription intention, disease diagnosis rate, etc.

・Response data can be viewed by the physician segment or by an individual physician.

・Timely retrieval of response data from the navigation board.

・Enables the analysis of the achievement of the project’s KPIs and issues arising during the prescription process and the consideration of the direction for the next project.

※Average of contents delivered in 2021